7,270 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,270 shares of the company's stock, valued at approximately $1,323,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Jamison Private Wealth Management Inc. bought a new position in Krystal Biotech during the second quarter worth $28,000. GAMMA Investing LLC increased its holdings in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc acquired a new position in shares of Krystal Biotech during the second quarter valued at about $28,000. Blue Trust Inc. lifted its stake in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Values First Advisors Inc. bought a new stake in shares of Krystal Biotech in the third quarter valued at about $53,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company's stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Price Performance

Shares of KRYS opened at $196.52 on Wednesday. The company has a market capitalization of $5.65 billion, a P/E ratio of 111.03 and a beta of 0.82. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The business's 50 day simple moving average is $179.69 and its 200-day simple moving average is $183.09.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. The business's revenue was up 879.9% on a year-over-year basis. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KRYS. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. Evercore ISI increased their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $202.29.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).